EP 2864788 A1 20150429 - BLOOD PLASMA BIOMARKERS FOR BEVACIZUMAB COMBINATION THERAPIES FOR TREATMENT OF BREAST CANCER
Title (en)
BLOOD PLASMA BIOMARKERS FOR BEVACIZUMAB COMBINATION THERAPIES FOR TREATMENT OF BREAST CANCER
Title (de)
BLUTPLASMABIOMARKER FÜR BEVACIZUMAB-KOMBINATIONSTHERAPIEN ZUR BEHANDLUNG VON BRUSTKREBS
Title (fr)
BIOMARQUEURS DU PLASMA SANGUIN POUR DES POLYTHÉRAPIES PAR BEVACIZUMAB POUR LE TRAITEMENT DU CANCER DU SEIN
Publication
Application
Priority
- US 201261664612 P 20120626
- US 201261697667 P 20120906
- EP 2013063094 W 20130624
Abstract (en)
[origin: WO2014001232A1] The present invention provides methods for improving the treatment effect of a chemotherapy regimen of a patient suffering from HER2 positive breast cancer, in particular locally recurrent or metastatic HER2 positive breast cancer, by adding bevacizumab (Avastin ®) to a chemotherapy regimen by determining the expression level, in particular the blood plasma expression level, of E-selectin, ICAM-1 or VEGFR-3 relative to control levels of patients diagnosed with HER2 positive breast cancer, in particular locally recurrent or metastatic HER2 positive breast cancer.
IPC 8 full level
G01N 33/574 (2006.01); A61K 35/00 (2006.01)
CPC (source: CN EP KR)
A61P 35/00 (2017.12 - EP); G01N 33/57415 (2013.01 - CN EP KR); G01N 2333/475 (2013.01 - CN EP KR)
Citation (search report)
See references of WO 2014001232A1
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
DOCDB simple family (publication)
WO 2014001232 A1 20140103; BR 112014032456 A2 20170627; CA 2871385 A1 20140103; CN 104364655 A 20150218; EP 2864788 A1 20150429; HK 1202334 A1 20150925; JP 2015522815 A 20150806; KR 20150024342 A 20150306; MX 2014014821 A 20150212; RU 2015102026 A 20160810
DOCDB simple family (application)
EP 2013063094 W 20130624; BR 112014032456 A 20130624; CA 2871385 A 20130624; CN 201380030336 A 20130624; EP 13730890 A 20130624; HK 15102817 A 20150319; JP 2015519012 A 20130624; KR 20147035874 A 20130624; MX 2014014821 A 20130624; RU 2015102026 A 20130624